Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
PDSB

PDSB - PDS Biotechnology Corp Stock Price, Fair Value and News

$0.900.00 (0.00%)
Market Closed

Price Targets

PDSB Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PDSB Price Action

Last 7 days

-3.2%

Last 30 days

11.1%

Last 90 days

-5.3%

Trailing 12 Months

-40%

PDSB RSI Chart

PDSB Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PDSB Valuation

Market Cap

44.1M

Price/Earnings (Trailing)

-1.26

Price/Sales (Trailing)

47.75

EV/EBITDA

-0.54

Price/Free Cashflow

-1.29

PDSB Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

PDSB Fundamentals

PDSB Revenue

Revenue (TTM)

871.9K

PDSB Earnings

Earnings (TTM)

-34.9M

Earnings Growth (Yr)

16.01%

Earnings Growth (Qtr)

4.5%

PDSB Profitability

EBT Margin

-4135.29%

Return on Equity

-369.02%

Return on Assets

-100.52%

Free Cashflow Yield

-77.61%

PDSB Investor Care

Shares Dilution (1Y)

30.93%

Diluted EPS (TTM)

-0.82

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2018851.3K944.4K917.6K871.9K
2017265.7K385.3K543.3K700.9K
201651.8K99.8K154.5K212.3K
201505.0K7.0K9.1K
2014003.4K2.9K
20130004.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About PDS Biotechnology Corp

PDSB
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. The company is developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.
 CEO
 WEBSITEpdsbiotech.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES26

PDS Biotechnology Corp Frequently Asked Questions

PDSB is the stock ticker symbol of PDS Biotechnology Corp. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of PDS Biotechnology Corp is 44.08 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check PDSB's fair value in chart for subscribers.

The fair value guage provides a quick view whether PDSB is over valued or under valued. Whether PDS Biotechnology Corp is cheap or expensive depends on the assumptions which impact PDS Biotechnology Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PDSB.

As of Wed Jan 28 2026, PDSB's PE ratio (Price to Earnings) is -1.26 and Price to Sales (PS) ratio is 47.75. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PDSB PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, PDS Biotechnology Corp has provided -0.424 (multiply by 100 for percentage) rate of return.